The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
1
Edited News | WHO
No evacuation order given before Kamal Adwan Hospital strike, says WHO
One of the last partially functional health centres in northern Gaza was reportedly hit again overnight into Friday by several strikes, leaving four health workers among the casualties and the dead, according to the UN World Health Organization (WHO).
2
1
2
Edited News , Press Conferences | OCHA
More than 280,000 people have been uprooted in northwest Syria in a matter of days following the sudden and massive offensive into Government-controlled areas led by Hayat Tahrir al-Sham (HTS), which is sanctioned by the Security Council as a terrorist group.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk has called on the Georgian authorities to respect and protect the rights to freedoms of expression and peaceful assembly following several nights of protests that were marred by violence, and dispersed using disproportionate, and in some cases unnecessary, force by the police in the capital, Tbilisi.
1
1
1
Edited News | OHCHR , UNOG
UN High Commissioner for Human Rights Volker Türk said today he was extremely concerned about the recent escalation in hostilities in northwest Syria, which further compounds the suffering endured by millions of civilians.
1
1
1
Edited News | OHCHR , WHO , OCHA
Syria escalation: Civilians face deadly attacks, health care in distress and aid access compromised
The ongoing escalation of violence in northwest Syria linked to the wider conflict in Gaza and Lebanon has left civilians dead and injured, hospitals “overwhelmed” and attacks on healthcare on the rise, the UN warned on Tuesday.
2
1
4
Press Conferences , Edited News | OCHA
Multiple unending conflicts, climate change and a glaring disregard for long-established international humanitarian law are set to leave a staggering 305 million people in need of lifesaving assistance next year, the UN’s top aid official warned on Wednesday.
Embargo Wednesday, 4 December 2024 at 0600 CET / 0000 ET
1
1
1
Edited News | OHCHR , UNOG
The UN Rights Office on Friday warned about the plight of civilians in Ukraine after further attacks on the country’s energy infrastructure.
1
1
1
Edited News | ITU
An international panel has been set up to protect undersea communications cables that are crucial for international trade and security, the UN International Telecommunication Union (ITU) said on Friday. The creation of the International Advisory Body for Submarine Cable Resilience comes amid an ongoing investigation into the severing of two fibre optic cables in the Baltic Sea, in less than 24 hours between 17 and 18 November.
2
1
2
Press Conferences , Edited News | ITU
An estimated 5.5 billion people have access to the internet in 2024, an increase of 227 million people based on revised estimates for 2023, the UN specialized agency for telecommunications, ITU, said on Wednesday.
2
1
2
Press Conferences , Edited News | UNAIDS
Launch of World AIDS Day Report 2024—Take The Rights Path
1
1
1
Edited News | OHCHR , UNOG
A joint report issued this morning by the UN Human Rights Office and the UN Assistance Mission in Afghanistan (UNAMA) paints a disturbing picture of the media landscape in the country since the Taliban takeover. UN Human Rights Chief Volker Türk says.
1
1
1
Edited News | OHCHR
UN human rights chief Volker Türk lent his weight to growing ceasefire calls in Lebanon on Tuesday, amid reports that the senior Israeli cabinet members were due to meet on a deal to end more than a year of conflict with Hezbollah militants, sparked by the war in Gaza